COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,137 Articles (22,693 medRxiv, 8,444 bioRxiv)

Most recent first Previous |  Page 573: Articles 5721-5730  | Next

Impact of SARS-CoV-2 on the microbiota of pregnant women and their infants
Leftwich, H. K., Vargas-Robles, D., Rojas Correa, M., Yap, Y. R., Bhattarai, S., Ward, D. V., Fujimori, G., Forconi, C. S., Yeboah, T., Carter, A., Kastrinakis, A., Asirwatham, A. M., Bucci, V., Moormann, A. M., Maldonado-Contreras, A.
10.1101/2022.11.01.22281810 — Posted: 2022-11-02
BIOLOGICAL RHYTHMS IN COVID-19 VACCINE EFFECTIVENESS
Hazan, G., Duek, O., Alapi, H., Mok, H., Ganniger, A., Ostendorf, E., Gierasch, C., Chodick, G., Greenberg, D., Haspel, J. A.
10.1101/2022.10.31.22281719 — Posted: 2022-11-02
Longitudinal proteomic investigation of COVID-19 vaccination
Wang, Y., Zhu, Q., Sun, R., Yi, X., Huang, L., Hu, Y., Ge, W., Gao, H., Ye, X., Song, Y., Shao, L., Li, Y., Li, J., Guo, T., Shi, J.
10.1101/2022.11.01.22281744 — Posted: 2022-11-02
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster
Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., Shi, P.-Y.
10.1101/2022.10.31.514580 — Posted: 2022-11-02
Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1
Miller, J., Hachmann, N., Collier, A.-r., Lasrado, N., Mazurek, C., Patio, R., Powers, O., Surve, N., Theiler, J., Korber, B., Barouch, D. H.
10.1101/2022.11.01.514722 — Posted: 2022-11-02
Prevalence and pattern of adverse events following COVID 19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria
Adamu, H., Adamu, A. A., Lawal, S., Bawa, I. A., Sani, A. M.
10.1101/2022.11.01.22281793 — Posted: 2022-11-02
SARS-CoV-2 antibody prevalence among industrial livestock operation workers and nearby community residents, North Carolina, USA, 2021-2022
Gigot, C. M., Pisanic, N., Kruczynski, K., Gregory Rivera, M., Spicer, K., Kurowski, K. M., Randad, P., Koehler, K., Clarke, W., Holmes, P., Hall, D. J., Hall, D., Heaney, C. D.
10.1101/2022.10.31.22281764 — Posted: 2022-11-01
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Qianqian, L., Jing, C., Kai, S., Ruixin, S., Jiayin, W., Hongmin, L., Yankai, Y., Jing, L., Qing, Y., YanYing, G., Jun, L., Ying, L., Junqing, Y., Chao, Y., Ying, L., Tao, W., Changen, L., Fei, W., Huiling, X.
10.1101/2022.10.30.22281713 — Posted: 2022-11-01
An implementation framework to improve the transparency and reproducibility of computational models of infectious diseases
Pokutnaya, D., Childers, B., Arcury-Quandt, A., Hochheiser, H., Van Panhuis, W. G.
10.1101/2022.10.28.22281671 — Posted: 2022-11-01
Between-Occupation Differences in Work-Related COVID-19 Mitigation Strategies over Time: Analysis of the Virus Watch Cohort in England and Wales
Beale, S., Yavlinsky, A., Hoskins, S. J., Nguyen, V., Byrne, T. E., Fong, W. L. E., Kovar, J., Van Tongeren, M., Aldridge, R. W., Hayward, A.
10.1101/2022.10.31.22281732 — Posted: 2022-11-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).